Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients
Christopher A. Yasenchak(Willamette Valley Cancer Institute and Research Center), Jonathan W. Friedberg(University of Rochester), Vivian Jean M. Cline(Texas Oncology), Jerome H. Goldschmidt, Rodolfo Bordoni(Georgia Cancer Specialists), Robert B. Sims(Seagen (United States)), Jingmin Liu(Southern Medical University), Dipti Patel‐Donnelly(Orthopaedic Research of Virginia), Mariana Sacchi(Genmab (United States)), Timothy Larson(The US Oncology Network), Ralph V. Boccia(Center for Cancer and Blood Disorders), Andres Forero‐Torres(Kirklin Clinic)
Cited by 16
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761